325P A phase II, open-label, single-center study of QL1706 plus platinum doublet chemotherapy with or without bevacizumab as first-line treatment in patients with advanced NSCLC: Data from EGFR wild-type cohort.

Subjects

Subjects :

*BEVACIZUMAB
*EPIDERMAL growth factor receptors
*PLATINUM
*NON-small-cell lung carcinoma
*CANCER chemotherapy

Details

Language :

English

ISSN :

09237534

Volume :

33

Database :

Academic Search Index

Journal :

Annals of Oncology

Publication Type :

Academic Journal

Accession number :

160398264

Full Text :

https://doi.org/10.1016/j.annonc.2022.10.364